Difference between revisions of "Team:DTU-Denmark/Description"

Line 45: Line 45:
 
     <div class="col-md-9 col-sm-10 colLeft"> <!-- LEFT -->
 
     <div class="col-md-9 col-sm-10 colLeft"> <!-- LEFT -->
 
         <div><a class="anchor" id="section-1"></a>
 
         <div><a class="anchor" id="section-1"></a>
−
        <h2 class="h2">Improvement and Characterization of Two Existing Parts</h2>
+
            <h2 class="h2">Parts list</h2>
 
              
 
              
 
             <blockquote class="visible-xs"> <!-- quote from masterhead duplicate -->
 
             <blockquote class="visible-xs"> <!-- quote from masterhead duplicate -->
Line 52: Line 52:
 
             </blockquote>
 
             </blockquote>
 
              
 
              
−
            <p><i>Improvement and Characterization of Two Existing Parts
 
−
                We have improved two existing BioBricks by successful removal of two illegal restriction sites and further improved the characterization.</i>
 
−
            </p>
 
  
−
            <p>
 
−
            In our laboratory work, we wanted to work with the two BioBricks; BBa_K530001 (CrtE gene) and BBa_K530002 (CrtI gene) created by the John Hopkins iGEM team 2011. The genes encode the two enzymes Geranylgeranyl Diphosphate Synthase and Phytoene Desaturase, respectively,  both from the wildtype strain of <i>xanthophyllomyces dendrorhous</i> used in the biosynthesis of B-Carotene.
 
−
            </p>
 
  
−
            <p>When looking into the specifications of these BioBricks, we realized that both genes contained illegal restriction sites.
 
−
            </p>
 
−
            <p>
 
−
            BBa_K530001 contained an AgeI restriction site making the part incompatible with the RFC25 Freiburg Standard. The RFC25 standard allows for in-frame assembly of protein domains.
 
−
            BBa_K530002 contained the illegal restriction site BglII making the part incompatible with the RFC21 Berkely Standard, which enables in-frame assembly of proteins.
 
−
            </p>
 
  
−
            <p>
 
−
            We wanted to overcome these obstacle by removing the illegal restriction sites from the above described Biobricks.
 
−
            </p>
 
−
 
−
            <h3 class="h3">How did we do it?</h3>
 
−
           
 
−
            <p>
 
−
            The illegal restriction sites were removed using site directed mutagenesis with primers containing nucleotide substitutions in the two restriction sites (see figure. Protocol https://static.igem.org/mediawiki/2014/b/b5/Wageningen_UR_protocols_Site_Directed_Mutagenesis.pdf).
 
−
            </p>
 
−
 
−
 
−
 
−
            <figure class="figure">
 
−
                <img id="img2" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/9/97/T--DTU-Denmark--sitedirected.png" alt="DESCRIPTION">
 
−
                <figcaption class="figure-caption"><strong>Figure 1:</strong> Primers overlapping the restriction sites are designed with a single nucleotide change to disrupt the restriction site. The primers anneal to the template plasmid and replicate while introducing the point mutation. The elongated plasmids are digested with the enzyme DpnI, which cleaves at the methylated sites breaking down the circular template, resulting in a higher transformation efficiency of the linear PCR product. </figcaption>
 
−
            </figure>
 
−
 
−
 
−
 
−
            <figure class="figure">
 
−
                <img id="img2" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/c/cc/T--DTU-Denmark--primers.jpg" alt="DESCRIPTION">
 
−
                <figcaption class="figure-caption"><strong>Table 1:</strong> Primers designed for removal of illegal restriction sites. Bold marks the nucleotide  substitution.</figcaption>
 
−
            </figure>
 
−
 
−
            <p>
 
−
            The new plasmid, BBa_K2117012, with the removed AgeI restriction site was double digested with the enzyme and SpeI to test if we had successfully removed the AgeI restriction site.
 
−
            </p>
 
−
 
−
 
−
 
−
 
−
            <figure class="figure">
 
−
                <img width="400" id="img2" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/4/42/T--DTU-Denmark--digestion.png" alt="DESCRIPTION">
 
−
                <figcaption class="figure-caption"><strong>Figure 2:</strong> AgeI + SpeI digestion. Electrophoresis on a 1% agarose gel showing the digestion of BBa_K2117012 (lane 1-3). BBa_530001 digested with AgeI + SpeI and undigested BBa_530001 were used as controls (lane 4+5). </figcaption>
 
−
            </figure>
 
−
 
−
 
−
 
−
 
−
            <p>
 
−
            The digestion showed the removal of the AgeI restriction site, shown on the gel picture by only one band on the BBa_K2117012 compared to two bands on the control BBa_K530001.
 
−
            </p>
 
−
 
−
            <p>
 
−
            BBa_K2117012 and BBa_K2117013 were sent for sequencing with the verification primers VR and VF2 primers to further verify the removal of the restriction sites.
 
−
            </p>
 
−
 
−
            <figure class="figure">
 
−
                <img width=500 id="img2" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/9/9c/T--DTU-Denmark--AgeI.JPG" alt="DESCRIPTION">
 
−
                <figcaption class="figure-caption"><strong>Figure 3:</strong> Sequencing alignment of BBa_530001 (top sequence) and BBa_K2117012 (bottom sequence). The alignment shows a nucleotide substitution in the AgeI restriction site. </figcaption>
 
−
            </figure>
 
−
 
−
            <figure class="figure">
 
−
                <img width=500 id="img2" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/a/ad/T--DTU-Denmark--BglII.jpg" alt="DESCRIPTION">
 
−
                <figcaption class="figure-caption"><strong>Figure 4:</strong> Sequencing alignment of BBa_530002 (top sequence) and BBa_K2117013 (bottom sequence). The alignment shows a nucleotide substitution in the BglII restriction site. </figcaption>
 
−
            </figure>
 
−
 
−
 
−
            <p>
 
−
            The sequencing results show a substitution in the restriction sites corresponding to the nucleotide substitution designed in the primers (table ??).
 
−
            </p>
 
−
 
−
            <p>
 
−
            By deleting the two restriction sites in the BBa_K2117012 and BBa_K2117013 we have made the two BioBricks compatible with RFC25 and RFC21 standards, respectively.
 
−
            </p>
 
−
 
−
            <h3 class="h3">Improvement of Characterization</h3>
 
−
 
−
 
−
            <p>
 
−
                While working with BBa_K530001 and BBa_K530002 we were struggling with assembly of the genes. Therefore, we sequenced the plasmids received in the distribution kit.
 
−
                </p>
 
−
 
−
            <p>
 
−
            Sequencing results of BBa_K530002 showed nucleotide substitutions in the prefix and a large deletion in the suffix.
 
−
            </p>
 
−
 
−
 
−
 
−
            <figure class="figure">
 
−
                <img width="500" id="img2" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/b/b5/T--DTU-Denmark--prefix.png" alt="DESCRIPTION">
 
−
                <figcaption class="figure-caption"><strong>Figure 5:</strong> Alignment of BBa_K530002 sequence received from the parts page (top) and sequencing results of BBa_K530002 from the distribution kit. Alignment shows many nucleotide substitutions in the prefix seuqence. </figcaption>
 
−
            </figure>
 
−
 
−
 
−
 
−
            <figure class="figure">
 
−
                <img width="500" id="img2" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/e/e2/T--DTU-Denmark--suffix.png" alt="DESCRIPTION">
 
−
                <figcaption class="figure-caption"><strong>Figure 6:</strong> Alignment of BBa_K530002 sequence received from the parts page (top) and sequencing results of BBa_K530002 from the distribution kit. Alignment shows a deletion in the suffix sequence. </figcaption>
 
−
            </figure>
 
−
 
−
 
−
 
−
 
−
            <p>
 
−
                The alterations in prefix and suffix make the BBa_K530002 incompatible with the BioBrick standard
 
−
            </p>
 
−
 
−
 
−
 
−
         
 
−
        </div> <!-- /overview-->
 
 
          
 
          
−
        <div><a class="anchor" id="section-2"></a>
 
−
        <h2 class="h2">Parts list</h2>
 
 
            
 
            
 
             <div class="grid-row">
 
             <div class="grid-row">
Line 271: Line 155:
 
                 </div>
 
                 </div>
 
             </div> <!-- /grid-row -->
 
             </div> <!-- /grid-row -->
 +
                     
 +
        </div> <!-- /overview-->
 +
       
 +
        <div><a class="anchor" id="section-2"></a>
 +
            <h2 class="h2">Improvement and Characterization of Two Existing Parts</h2>
 +
            <p><i>Improvement and Characterization of Two Existing Parts
 +
                We have improved two existing BioBricks by successful removal of two illegal restriction sites and further improved the characterization.</i>
 +
            </p>
 +
 +
            <p>
 +
            In our laboratory work, we wanted to work with the two BioBricks; BBa_K530001 (CrtE gene) and BBa_K530002 (CrtI gene) created by the John Hopkins iGEM team 2011. The genes encode the two enzymes Geranylgeranyl Diphosphate Synthase and Phytoene Desaturase, respectively,  both from the wildtype strain of <i>xanthophyllomyces dendrorhous</i> used in the biosynthesis of B-Carotene.
 +
            </p>
 +
 +
            <p>When looking into the specifications of these BioBricks, we realized that both genes contained illegal restriction sites.
 +
            </p>
 +
            <p>
 +
            BBa_K530001 contained an AgeI restriction site making the part incompatible with the RFC25 Freiburg Standard. The RFC25 standard allows for in-frame assembly of protein domains.
 +
            BBa_K530002 contained the illegal restriction site BglII making the part incompatible with the RFC21 Berkely Standard, which enables in-frame assembly of proteins.
 +
            </p>
 +
 +
            <p>
 +
            We wanted to overcome these obstacle by removing the illegal restriction sites from the above described Biobricks.
 +
            </p>
 +
 +
            <h3 class="h3">How did we do it?</h3>
 
              
 
              
 +
            <p>
 +
            The illegal restriction sites were removed using site directed mutagenesis with primers containing nucleotide substitutions in the two restriction sites (see figure. Protocol https://static.igem.org/mediawiki/2014/b/b5/Wageningen_UR_protocols_Site_Directed_Mutagenesis.pdf).
 +
            </p>
 +
 +
 +
 +
            <figure class="figure">
 +
                <img id="img1" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/9/97/T--DTU-Denmark--sitedirected.png" alt="DESCRIPTION">
 +
                <figcaption class="figure-caption"><strong>Figure 1:</strong> Primers overlapping the restriction sites are designed with a single nucleotide change to disrupt the restriction site. The primers anneal to the template plasmid and replicate while introducing the point mutation. The elongated plasmids are digested with the enzyme DpnI, which cleaves at the methylated sites breaking down the circular template, resulting in a higher transformation efficiency of the linear PCR product. </figcaption>
 +
            </figure>
 
              
 
              
 +
            <!-- The Modal with same picture-->
 +
            <div id="img1Modal" class="modal">
 +
                <span class="close img1">×</span>
 +
                <img class="modal-content" id="img1Img">
 +
                <div class="caption">DESCRIPTION</div>
 +
            </div>
 +
 +
 +
 +
            <figure class="figure">
 +
                <img id="img2" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/c/cc/T--DTU-Denmark--primers.jpg" alt="DESCRIPTION">
 +
                <figcaption class="figure-caption"><strong>Table 1:</strong> Primers designed for removal of illegal restriction sites. Bold marks the nucleotide  substitution.</figcaption>
 +
            </figure>
 +
           
 +
            <!-- The Modal with same picture-->
 +
            <div id="img2Modal" class="modal">
 +
                <span class="close img2">×</span>
 +
                <img class="modal-content" id="img2Img">
 +
                <div class="caption">DESCRIPTION</div>
 +
            </div>
 +
 +
            <p>
 +
            The new plasmid, BBa_K2117012, with the removed AgeI restriction site was double digested with the enzyme and SpeI to test if we had successfully removed the AgeI restriction site.
 +
            </p>
 +
 +
 +
 +
 +
            <div class="row">
 +
                <div class="col-md-6">
 +
                    <figure class="figure">
 +
                        <img width="400" id="img3" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/4/42/T--DTU-Denmark--digestion.png" alt="DESCRIPTION">
 +
                        <figcaption class="figure-caption"><strong>Figure 2:</strong> AgeI + SpeI digestion. Electrophoresis on a 1% agarose gel showing the digestion of BBa_K2117012 (lane 1-3). BBa_530001 digested with AgeI + SpeI and undigested BBa_530001 were used as controls (lane 4+5). </figcaption>
 +
                                </figure>
 +
                               
 +
                        <!-- The Modal with same picture-->
 +
                    <div id="img3Modal" class="modal">
 +
                        <span class="close img3">×</span>
 +
                        <img class="modal-content" id="img3Img">
 +
                        <div class="caption">DESCRIPTION</div>
 +
                    </div>
 +
                </div>
 +
            </div>
 +
 +
 +
 +
 
             <p>
 
             <p>
−
                Has ut facer debitis, quo eu agam purto. In eum justo aeterno. Sea ut atqui efficiantur, mandamus deseruisse at est, erat natum cum eu. Quot numquam in vel. Salutatus euripidis moderatius qui ex, eu tempor volumus vituperatoribus has, ius ea ullum facer corrumpit.
+
            The digestion showed the removal of the AgeI restriction site, shown on the gel picture by only one band on the BBa_K2117012 compared to two bands on the control BBa_K530001.  
 
             </p>
 
             </p>
  
−
        </div>
+
            <p>
 +
            BBa_K2117012 and BBa_K2117013 were sent for sequencing with the verification primers VR and VF2 primers to further verify the removal of the restriction sites.
 +
            </p>
 +
 
 +
            <div class="row">
 +
                <div class="col-md-12">
 +
                    <figure class="figure">
 +
                        <img id="img4" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/9/9c/T--DTU-Denmark--AgeI.JPG" alt="DESCRIPTION">
 +
                        <figcaption class="figure-caption"><strong>Figure 3:</strong> Sequencing alignment of BBa_530001 (top sequence) and BBa_K2117012 (bottom sequence). The alignment shows a nucleotide substitution in the AgeI restriction site. </figcaption>
 +
                    </figure>
 +
                   
 +
                    <!-- The Modal with same picture-->
 +
                    <div id="img4Modal" class="modal">
 +
                        <span class="close img4">×</span>
 +
                        <img class="modal-content" id="img4Img">
 +
                        <div class="caption">DESCRIPTION</div>
 +
                    </div>
 +
                </div>           
 +
                           
 +
                <div class="col-md-12">
 +
                    <figure class="figure">
 +
                        <img id="img5" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/a/ad/T--DTU-Denmark--BglII.jpg" alt="DESCRIPTION">
 +
                        <figcaption class="figure-caption"><strong>Figure 4:</strong> Sequencing alignment of BBa_530002 (top sequence) and BBa_K2117013 (bottom sequence). The alignment shows a nucleotide substitution in the BglII restriction site. </figcaption>
 +
                    </figure>
 +
                                <!-- The Modal with same picture-->
 +
                    <div id="img5Modal" class="modal">
 +
                        <span class="close img5">×</span>
 +
                        <img class="modal-content" id="img5Img">
 +
                        <div class="caption">DESCRIPTION</div>
 +
                    </div>
 +
                </div>
 +
               
 +
            </div>
 +
 
  
−
        <div><a class="anchor" id="section-4"></a>
 
−
        <h2 class="h2">Section 4</h2>
 
 
             <p>
 
             <p>
−
                 Has ut facer debitis, quo eu agam purto. In eum justo aeterno. Sea ut atqui efficiantur, mandamus deseruisse at est, erat natum cum eu. Quot numquam in vel. Salutatus euripidis moderatius qui ex, eu tempor volumus vituperatoribus has, ius ea ullum facer corrumpit.
+
                 The sequencing results show a substitution in the restriction sites corresponding to the nucleotide substitution designed in the primers (table ??).  
 
             </p>
 
             </p>
−
        </div>
 
  
−
        <div><a class="anchor" id="section-5"></a>
 
−
        <h2 class="h2">Section 5</h2>
 
 
             <p>
 
             <p>
−
                 Has ut facer debitis, quo eu agam purto. In eum justo aeterno. Sea ut atqui efficiantur, mandamus deseruisse at est, erat natum cum eu. Quot numquam in vel. Salutatus euripidis moderatius qui ex, eu tempor volumus vituperatoribus has, ius ea ullum facer corrumpit.
+
                 By deleting the two restriction sites in the BBa_K2117012 and BBa_K2117013 we have made the two BioBricks compatible with RFC25 and RFC21 standards, respectively.
 
             </p>
 
             </p>
−
        </div>
 
  
−
        <div><a class="anchor" id="section-6"></a>
+
            <h3 class="h3">Improvement of Characterization</h3>
−
        <h2 class="h2">Section 6</h2>
+
 
 
             <p>
 
             <p>
−
                 Has ut facer debitis, quo eu agam purto. In eum justo aeterno. Sea ut atqui efficiantur, mandamus deseruisse at est, erat natum cum eu. Quot numquam in vel. Salutatus euripidis moderatius qui ex, eu tempor volumus vituperatoribus has, ius ea ullum facer corrumpit.
+
                 While working with BBa_K530001 and BBa_K530002 we were struggling with assembly of the genes. Therefore, we sequenced the plasmids received in the distribution kit.  
 
             </p>
 
             </p>
−
        </div>
 
  
−
        <div><a class="anchor" id="section-7"></a>
 
−
        <h2 class="h2">Section 7</h2>
 
 
             <p>
 
             <p>
−
                 Has ut facer debitis, quo eu agam purto. In eum justo aeterno. Sea ut atqui efficiantur, mandamus deseruisse at est, erat natum cum eu. Quot numquam in vel. Salutatus euripidis moderatius qui ex, eu tempor volumus vituperatoribus has, ius ea ullum facer corrumpit.
+
                 Sequencing results of BBa_K530002 showed nucleotide substitutions in the prefix and a large deletion in the suffix.  
 +
            </p>
 +
 
 +
 
 +
 
 +
            <figure class="figure">
 +
                <img id="img6" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/b/b5/T--DTU-Denmark--prefix.png" alt="DESCRIPTION">
 +
                <figcaption class="figure-caption"><strong>Figure 5:</strong> Alignment of BBa_K530002 sequence received from the parts page (top) and sequencing results of BBa_K530002 from the distribution kit. Alignment shows many nucleotide substitutions in the prefix seuqence. </figcaption>
 +
            </figure>
 +
           
 +
            <div id="img6Modal" class="modal">
 +
                <span class="close img6">×</span>
 +
                <img class="modal-content" id="img6Img">
 +
                <div class="caption">DESCRIPTION</div>
 +
            </div>
 +
 
 +
 
 +
            <figure class="figure">
 +
                <img id="img7" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/e/e2/T--DTU-Denmark--suffix.png" alt="DESCRIPTION">
 +
                <figcaption class="figure-caption"><strong>Figure 6:</strong> Alignment of BBa_K530002 sequence received from the parts page (top) and sequencing results of BBa_K530002 from the distribution kit. Alignment shows a deletion in the suffix sequence. </figcaption>
 +
            </figure>
 +
           
 +
            <div id="img7Modal" class="modal">
 +
                <span class="close img7">×</span>
 +
                <img class="modal-content" id="img7Img">
 +
                <div class="caption">DESCRIPTION</div>
 +
            </div>
 +
 
 +
            <p>
 +
                The alterations in prefix and suffix make the BBa_K530002 incompatible with the BioBrick standard
 
             </p>
 
             </p>
 
         </div>
 
         </div>
 +
 +
 +
 
     </div> <!-- /LEFT -->
 
     </div> <!-- /LEFT -->
 
      
 
      
Line 313: Line 335:
 
             <li><a href="#section-1">Improvement and Charactization</a></li>
 
             <li><a href="#section-1">Improvement and Charactization</a></li>
 
             <li><a href="#section-2">Parts list</a></li>
 
             <li><a href="#section-2">Parts list</a></li>
−
             <li><a href="#section-3">Section 3</a></li>
+
             <li><a href="#section-3">Improvement of Part</a></li>
 
             <li><a href="#section-4">Section 4</a></li>
 
             <li><a href="#section-4">Section 4</a></li>
 
             <li><a href="#section-5">Section 5</a></li>
 
             <li><a href="#section-5">Section 5</a></li>

Revision as of 14:50, 19 October 2016

New HTML template for the wiki




Bootstrap Example

Title

leader under the title, short introduction.


Parts list

Quote Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer posuere erat a ante.

Someone famous in Source Title
BBa_K2117000

Constitutive TEF1 promoter

BBa_K2117001

Human proinsulin codon-optimised for Y. lipolytica

BBa_K2117002

Composite part consisting of the TEF1 promoter and the human proinsulin gene

BBa_K2117003

hrGFP codon-optimized for Y. lipolytica

BBa_K2117004

hrGFP expressed by the constitutive TEF1 promoter

BBa_K2117005

SCR1'-tRNA promoter expressing gRNA

BBa_K2117009

Semi-synthetic shuttle vector pSB1A8YL

BBa_K2117010

Composite part of TEF1 and enhanced YFP

BBa_K2117011

Composite part of TEF1 and eCFP

BBa_K2117012

Improved CrtE

BBa_K2117013

Improved CrtI

Improvement and Characterization of Two Existing Parts

Improvement and Characterization of Two Existing Parts We have improved two existing BioBricks by successful removal of two illegal restriction sites and further improved the characterization.

In our laboratory work, we wanted to work with the two BioBricks; BBa_K530001 (CrtE gene) and BBa_K530002 (CrtI gene) created by the John Hopkins iGEM team 2011. The genes encode the two enzymes Geranylgeranyl Diphosphate Synthase and Phytoene Desaturase, respectively, both from the wildtype strain of xanthophyllomyces dendrorhous used in the biosynthesis of B-Carotene.

When looking into the specifications of these BioBricks, we realized that both genes contained illegal restriction sites.

BBa_K530001 contained an AgeI restriction site making the part incompatible with the RFC25 Freiburg Standard. The RFC25 standard allows for in-frame assembly of protein domains. BBa_K530002 contained the illegal restriction site BglII making the part incompatible with the RFC21 Berkely Standard, which enables in-frame assembly of proteins.

We wanted to overcome these obstacle by removing the illegal restriction sites from the above described Biobricks.

How did we do it?

The illegal restriction sites were removed using site directed mutagenesis with primers containing nucleotide substitutions in the two restriction sites (see figure. Protocol https://static.igem.org/mediawiki/2014/b/b5/Wageningen_UR_protocols_Site_Directed_Mutagenesis.pdf).

DESCRIPTION
Figure 1: Primers overlapping the restriction sites are designed with a single nucleotide change to disrupt the restriction site. The primers anneal to the template plasmid and replicate while introducing the point mutation. The elongated plasmids are digested with the enzyme DpnI, which cleaves at the methylated sites breaking down the circular template, resulting in a higher transformation efficiency of the linear PCR product.
DESCRIPTION
Table 1: Primers designed for removal of illegal restriction sites. Bold marks the nucleotide substitution.

The new plasmid, BBa_K2117012, with the removed AgeI restriction site was double digested with the enzyme and SpeI to test if we had successfully removed the AgeI restriction site.

DESCRIPTION
Figure 2: AgeI + SpeI digestion. Electrophoresis on a 1% agarose gel showing the digestion of BBa_K2117012 (lane 1-3). BBa_530001 digested with AgeI + SpeI and undigested BBa_530001 were used as controls (lane 4+5).

The digestion showed the removal of the AgeI restriction site, shown on the gel picture by only one band on the BBa_K2117012 compared to two bands on the control BBa_K530001.

BBa_K2117012 and BBa_K2117013 were sent for sequencing with the verification primers VR and VF2 primers to further verify the removal of the restriction sites.

DESCRIPTION
Figure 3: Sequencing alignment of BBa_530001 (top sequence) and BBa_K2117012 (bottom sequence). The alignment shows a nucleotide substitution in the AgeI restriction site.
DESCRIPTION
Figure 4: Sequencing alignment of BBa_530002 (top sequence) and BBa_K2117013 (bottom sequence). The alignment shows a nucleotide substitution in the BglII restriction site.

The sequencing results show a substitution in the restriction sites corresponding to the nucleotide substitution designed in the primers (table ??).

By deleting the two restriction sites in the BBa_K2117012 and BBa_K2117013 we have made the two BioBricks compatible with RFC25 and RFC21 standards, respectively.

Improvement of Characterization

While working with BBa_K530001 and BBa_K530002 we were struggling with assembly of the genes. Therefore, we sequenced the plasmids received in the distribution kit.

Sequencing results of BBa_K530002 showed nucleotide substitutions in the prefix and a large deletion in the suffix.

DESCRIPTION
Figure 5: Alignment of BBa_K530002 sequence received from the parts page (top) and sequencing results of BBa_K530002 from the distribution kit. Alignment shows many nucleotide substitutions in the prefix seuqence.
DESCRIPTION
Figure 6: Alignment of BBa_K530002 sequence received from the parts page (top) and sequencing results of BBa_K530002 from the distribution kit. Alignment shows a deletion in the suffix sequence.

The alterations in prefix and suffix make the BBa_K530002 incompatible with the BioBrick standard

  • FIND US AT:
Facebook Twitter
  • DTU BIOBUILDERS
  • DENMARK
  • DTU - SØLTOFTS PLADS, BYGN. 221/002
  • 2800 KGS. LYNGBY

  • E-mail:
  • dtu-biobuilders-2016@googlegroups.com
  • MAIN SPONSORS:
Lundbeck fundation DTU blue dot Lundbeck fundation Lundbeck fundation